Sutureless, Laser-Assisted Bypass Surgery on Beating Heart Proves Safe and Effective in Landmark Trial

Coronary artery disease remains the leading cause of death globally, and for its most severe forms, the gold standard treatment is a brutal mechanical intervention: coronary artery bypass grafting (CABG). For decades, this procedure has required surgeons to crack open the patient's chest, stop the heart, reroute the blood through a cardiopulmonary bypass machine, and meticulously hand-sew tiny blood vessels together to create a detour around the blockage. While highly effective at preventing heart attacks, the sheer trauma of the surgery carries significant risks of stroke, infection, and cognitive decline, alongside a grueling months-long recovery.[1][4]

A new era for cardiovascular surgery is now emerging, promising to make the trauma of traditional open-heart bypass a relic of the past. On July 16, 2026, the one-year results of the SAFE-CAB II prospective clinical trial were published in The Journal of Thoracic and Cardiovascular Surgery. The landmark data confirms that a revolutionary sutureless, laser-assisted bypass technique is both safe and highly effective in human patients, marking a major milestone in the quest to modernize cardiac care.[1][3][4]

The breakthrough technology at the center of the trial is the ELANA Heart Bypass System, developed by the Dutch clinical-stage medical technology company AMT Medical. Designed to eliminate the need for complex hand-suturing, the system allows surgeons to perform the delicate vessel connection—known as an anastomosis—on a beating heart. By removing the need to stop the heart, the technology fundamentally alters the risk profile of the operation.[2][4]

The mechanism behind the ELANA system represents a radical departure from centuries of surgical tradition. Instead of using a needle and thread to stitch the donor vessel to the blocked coronary artery, the surgeon uses a proprietary titanium clip. This clip securely attaches the new graft vessel to the outside of the coronary artery, creating a perfect seal without penetrating the inner blood vessel wall.[2][5]

Once the clip is firmly in place, the surgeon introduces an excimer laser catheter through the graft vessel. The fiber-optic laser is fired, punching a precise, microscopic hole—an arteriotomy—through the walls of both vessels. This instantly opens the new channel, allowing blood to flow through the bypass and around the blockage. The laser vaporizes the tissue without burning or damaging the surrounding cellular structures.[5][6]

Crucially, because the physical connection is fully secured by the titanium clip before the laser opens the artery, the procedure is entirely non-occlusive. Blood continues to flow to the heart muscle throughout the entire operation. The surgeon never has to clamp the coronary artery or interrupt the patient's circulation, which is the primary reason the heart can continue beating normally during the procedure.[6][7]

To prove the safety and viability of this science-fiction-like approach, the SAFE-CAB II trial enrolled 71 patients undergoing elective CABG between June 2023 and September 2024. The procedures were conducted at St. Antonius Hospital in the Netherlands and Deutsches Herzzentrum der Charité in Germany. The patients had an average age of 71, and surgeons performed an average of 3.5 bypass connections per patient.[3][4]

The primary endpoint of the trial was safety, specifically measuring device-related major adverse cardiac events (MACE) over a one-year period. MACE is a composite metric that includes cardiac death, heart attacks, or the need for repeat revascularization procedures. At the one-year mark, device-related MACE occurred in just 2.9% of the patients treated with the ELANA system.[1][3]

This 2.9% complication rate was statistically non-inferior to the historical surgical benchmark for traditional hand-sewn bypasses (p = 0.0033). The data definitively proved that the laser-and-clip method does not introduce excess risk to the patient. Overall MACE across all coronary territories in the trial was 8.7%, which perfectly aligns with the expected baseline rates for a patient population of this age and disease severity.[1][4]

While safety is paramount, a bypass is only useful if it remains open and functional over time. In surgical terms, this is known as patency. At the six-month follow-up, coronary angiography revealed that 92.5% of the ELANA bypass connections across the full trial cohort were fully patent, allowing unobstructed blood flow to the heart muscle.[3][4]

Even more promising, in a subgroup of patients who were treated with the latest-generation laser catheter, the patency rate rose to an exceptional 97.5%. This success rate matches the upper echelon of outcomes reported for the absolute best hand-sewn bypasses performed by elite cardiothoracic surgeons, proving that the sutureless device can compete with the gold standard of human dexterity.[1][4]

In a subset of patients where the standard angiogram provided an ambiguous result, researchers utilized intravascular ultrasound to look directly inside the blood vessels. The ultrasound imaging confirmed that the bypass connections were fully open and completely unobstructed by scar tissue or intimal hyperplasia, a common cause of graft failure in experimental cardiac devices.[3]

While the SAFE-CAB II trial was performed via traditional open-chest sternotomy to ensure maximum safety and visibility during this early phase of human testing, the ultimate goal of the ELANA system is far more ambitious. The technology was explicitly designed to be the foundational enabler for fully endoscopic and robotic bypass surgeries, where the chest is never opened.[2][7]

For years, surgeons have known that minimally invasive, beating-heart CABG is better for the patient, but hand-sewing a two-millimeter vessel on a moving, beating heart through a small keyhole incision is notoriously difficult. It requires extreme technical skill, which has severely limited its widespread adoption. By replacing the needle and thread with a standardized, reproducible six-step clip-and-laser system, AMT Medical removes the need for this extreme surgical dexterity.[5][7]

The economic implications of this shift are staggering. Health economists and internal assessments estimate that by enabling minimally invasive, same-day-discharge bypass procedures, the technology could reduce direct CABG-related hospital costs by 35% to 50%. These savings are driven by the elimination of the cardiopulmonary bypass machine, shorter operating room times, and the drastic reduction of intensive care unit stays.[1][2]

For the patients, the benefits are even more profound. Instead of enduring a cracked sternum that requires months of painful healing, heavy pain medication, and severe physical restrictions, patients undergoing a robotic, sutureless bypass could potentially return home within days. The indirect economic benefits of returning working-age patients to their jobs and daily lives faster present a massive value proposition for global healthcare systems.[2][4]

Despite the landmark results, transparent uncertainties remain. One-year data is a crucial and celebrated milestone, but coronary bypasses are expected to last for decades. Long-term follow-up studies will be required to ensure that the permanent titanium clip does not induce late-stage vessel narrowing or unexpected inflammatory responses over a ten-to-twenty-year horizon.[3][6]

Additionally, the system must now be rigorously tested in the actual minimally invasive and robotic settings it was designed to facilitate. Clinical trials must prove that average cardiothoracic surgeons can easily learn the six-step process and achieve the same 97.5% patency rates when operating through small ports rather than an open chest.[2][4]

Armed with a recent $25 million Series B funding round, AMT Medical is aggressively pursuing these next steps. The company is utilizing the capital to secure CE marking in Europe by 2026, which would clear the device for commercial use during open surgical procedures, while simultaneously laying the groundwork for initial clinical trials in the United States.[2]

If these subsequent trials replicate the success of SAFE-CAB II in a robotic setting, the excimer laser and titanium clip will fundamentally transform cardiovascular care. By making open-heart bypass obsolete, this technology stands to save healthcare systems billions while sparing hundreds of thousands of patients from the trauma of the surgeon's saw.[1][2][4]